Venlafaxine-Associated Hepatitis
The DOI matches its Crossref record.
Abstract
Letters7 March 2000Venlafaxine-Associated HepatitisXavier Cardona, Asunción Avila, and Pere CastellanosXavier CardonaConsorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Cardona)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Avila)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Castellanos), Asunción AvilaConsorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Cardona)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Avila)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Castellanos), and Pere CastellanosConsorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Cardona)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Avila)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Castellanos)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-5-200003070-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We agree with Horsmans and colleagues, who suggest that liver function should be regularly monitored in patients receiving venlafaxine. We report another case of acute hepatic injury with a prominent element of cholestasis in a patient taking this drug.On 15 April 1999, a 78-year-old man was admitted to our hospital with icteric acute hepatitis. His medical history revealed Parkinson disease that was being treated with levodopa and pergolide and a major depression episode that had been treated with electroconvulsive therapy 2 months before admission. On 6 March, he had begun receiving venlafaxine at an initial dosage ...Reference1. Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis [Letter]. Ann Intern Med. 1999;130:944. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Cardona)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Avila)Consorci de l'Hospital de la Creu Roja; Barcelona, 08906 Spain (Castellanos) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoVenlaxafine-Associated Hepatitis Yves Horsmans , Michel De Clercq , and Christine Sempoux Metrics Cited ByClinical Impact of Depression in CirrhosisPsychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicityVenlafaxine-Induced Cytotoxicity Towards Isolated Rat Hepatocytes Involves Oxidative Stress and Mitochondrial/Lysosomal DysfunctionDrug-Induced Liver DiseaseReview article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantationHepatotoxicity of Psychotropic Drugs and Drugs of AbuseVenlafaxine-induced Cholestatic HepatitisHepatic injury due to drugs, herbal compounds, chemicals and toxinsVenlafaxine-Induced Hepatotoxicity in a Patient with Ulcerative ColitisPharmacokinetic Changes of Psychotropic Drugs in Patients with Liver DiseaseHepatitis colestásica por venlafaxinaReview of Duloxetine and Venlafaxine in DepressionAnswers to the Most Common Questions About the Hepatic Safety Profile of DuloxetineAntidepressant-lnduced Liver InjuryAn Overview of Psychiatric Issues in Liver Disease for the Consultation–Liaison PsychiatristHepatitis Associated with Low-Dose Venlafaxine for Postmenopausal Vasomotor SymptomsFatal Venlafaxine Overdose With Acinar Zone 3 Liver Cell NecrosisUse of psychotropics in special patient groupsHepatotoxicity possibly due to paracetamol with carbamazepineLow-dose venlafaxine-associated liver toxicity in chronic hepatitisTreatment of Anxiety and Depression in Transplant PatientsDrug-Induced HepatotoxicityFulminant liver diseaseHepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactionsHepatic injury and pancreatitis during treatment with serotonin reuptake inhibitorsAntidepressant-induced hepatotoxicityComprehensive Review of Hepatitis C for Psychiatrists: Risks, Screening, Diagnosis, Treatment, and Interferon-Based Therapy ComplicationsDrug-induced liver diseaseVenlafaxine 7 March 2000Volume 132, Issue 5Page: 417KeywordsBilirubinHepatitisHepatitis ALevodopaLiverLiver function testsParkinson diseasePhosphatasesSerum glutamic oxaloacetic transaminaseUltrasound imaging Issue Published: 7 March 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Antidepressant-Induced Liver Injury: A Review for Clinicians
Voican, C. S., Corruble, E., Naveau, S., & Perlemuter, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13050709 · Cited by 275
Mullish, B. H., Kabir, M. S., Thursz, M. R., & Dhar, A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12925 · Cited by 144
Antidepressant-induced hepatotoxicity
Lucena, M. I., Carvajal, A., Andrade, R. J., & Velasco, A. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.3.249 · Cited by 78
Answers to the Most Common Questions About the Hepatic Safety Profile of Duloxetine
Wohlreich, M. M., Acharya, N., Strombom, I., Kuritzky, L., Robinson, M., Heinloth, A. N., Regev, A., & Wernicke, J. F. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1803 · Cited by 12
Metadata
- Authors
- Cardona, X., Avila, A., & Castellanos, P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2000-03-07
- Volume
- 132
- Issue
- 5
- Pages
- 417
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2093374310
- Cited by
- 37
- References
- 0
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venlafaxine-Associated Hepatitis. https://app.cochat.ai/papers/10.7326/0003-4819-132-5-200003070-00016
- The paper
- Cardona, X., Avila, A., & Castellanos, P. (2000). Venlafaxine-Associated Hepatitis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-132-5-200003070-00016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.